Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. Signal., 30 July 2013
Vol. 6, Issue 286, p. ra63
miR-29 Acts as a Decoy in Sarcomas to Protect the Tumor Suppressor A20 mRNA from Degradation by HuR
Mumtaz Y. Balkhi1,2,
O. Hans Iwenofu2,3,
Katherine J. Ladner1,2,
Dawn S. Chandler5,
Peter J. Houghton5,
Cheryl A. London6,
Carlo M. Croce1,2,
Charles Keller8, and
Denis C. Guttridge1,2*
1 Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, The Ohio State University, Columbus, OH 43210, USA. 2 Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. 3 Department of Pathology and Laboratory Medicine, The Ohio State University, Columbus, OH 43210, USA. 4 Barrow Neurological Institute, 350 West Thomas Road, Phoenix, AZ 85013, USA. 5 Center for Pediatric Oncology, Nationwide Childrens Hospital, Columbus, OH 43205, USA. 6 Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA. 7 Department of Surgery, The Ohio State University, Columbus, OH 43210, USA. 8 Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.
In sarcoma, the activity of NF-B (nuclear factor B) reduces the abundance of the microRNA (miRNA) miR-29. The tumor suppressor A20 [also known as TNFAIP3 (tumor necrosis factor–α–induced protein 3)] inhibits an upstream activator of NF-B and is often mutated in lymphomas. In a panel of human sarcoma cell lines, we found that the activation of NF-B was increased and, although the abundance of A20 protein and mRNA was decreased, the gene encoding A20 was rarely mutated. The 3' untranslated region (UTR) of A20 mRNA has conserved binding sites for both of the miRNAs miR-29 and miR-125. Whereas the expression of miR-125 was increased in human sarcoma tissue, that of miR-29 was decreased in most samples. Overexpression of miR-125 decreased the abundance of A20 mRNA, whereas reconstituting miR-29 in sarcoma cell lines increased the abundance of A20 mRNA and protein. By interacting directly with the RNA binding protein HuR (human antigen R; also known as ELAVL1), miR-29 prevented HuR from binding to the A20 3'UTR and recruiting the RNA degradation complex RISC (RNA-induced silencing complex), suggesting that miR-29 can act as a decoy for HuR, thus protecting A20 transcripts. Decreased miR-29 and A20 abundance in sarcomas correlated with increased activity of NF-B and decreased expression of genes associated with differentiation. Together, the findings reveal a unique role of miR-29 and suggest that its absence may contribute to sarcoma tumorigenesis.
Citation: M. Y. Balkhi, O. H. Iwenofu, N. Bakkar, K. J. Ladner, D. S. Chandler, P. J. Houghton, C. A. London, W. Kraybill, D. Perrotti, C. M. Croce, C. Keller, D. C. Guttridge, miR-29 Acts as a Decoy in Sarcomas to Protect the Tumor Suppressor A20 mRNA from Degradation by HuR. Sci. Signal.6, ra63 (2013).
Nam Hee Kim, Hyun Sil Kim, Nam-Gyun Kim, Inhan Lee, Hyung-Seok Choi, Xiao-Yan Li, Shi Eun Kang, So Young Cha, Joo Kyung Ryu, Jung Min Na, Changbum Park, Kunhong Kim, Sanghyuk Lee, Barry M. Gumbiner, Jong In Yook, and Stephen J. Weiss (1 November 2011) Sci. Signal.4 (197), ra71.
[DOI: 10.1126/scisignal.2001744] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »